
NYSEHealthcareMedical - Devices
أحدث البيانات المتاحة
85.21 US$
+0.97 US$ · +1.15%
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
الإغلاق السابق
85.21 US$
+0.97 US$ · +1.15%
بعد ساعات التداول
85.19 US$
−0.02 US$ · -0.02%
9 أكتوبر، 5:40 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
نطاق اليوم
السعر الحالي 85.21 US$
نطاق 52 أسبوعًا
السعر الحالي 85.21 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
34
مرتفع السعر
المشاعر
65
صعودي
المخاطر
21
مخاطر متوسطة
الزخم
55
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
نطاق اليوم
السعر الحالي 85.21 US$
نطاق 52 أسبوعًا
السعر الحالي 85.21 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 6.07 مليار USD | 5.44 مليار USD | 5.01 مليار USD | 5.38 مليار USD | 5.23 مليار USD |
| تكلفة البضاعة المباعة | 1.33 مليار USD | 1.12 مليار USD | 1.04 مليار USD | 1.17 مليار USD | 1.23 مليار USD |
| الربح الإجمالي | 4.74 مليار USD | 4.32 مليار USD | 3.97 مليار USD | 4.22 مليار USD | 4.01 مليار USD |
| البحث والتطوير | 1.08 مليار USD | 1.05 مليار USD | 962.9 مليون USD | 945.2 مليون USD | 903.1 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 2.09 مليار USD | 1.79 مليار USD | 1.58 مليار USD | 1.57 مليار USD | 1.49 مليار USD |
| نفقات التشغيل | 3.1 مليار USD | 2.94 مليار USD | 2.55 مليار USD | 2.51 مليار USD | 2.4 مليار USD |
| دخل الفوائد | 148.4 مليون USD | 120.3 مليون USD | 67.2 مليون USD | 35.5 مليون USD | 17.4 مليون USD |
| مصاريف الفوائد | — | 19.8 مليون USD | 17.6 مليون USD | 26.2 مليون USD | 24.8 مليون USD |
| الاستهلاك والإطفاء | 156.6 مليون USD | 155.2 مليون USD | 144.9 مليون USD | 139.6 مليون USD | 134.8 مليون USD |
| الدخل التشغيلي | 1.64 مليار USD | 1.38 مليار USD | 1.43 مليار USD | 1.7 مليار USD | 1.61 مليار USD |
| صافي الدخل | 1.07 مليار USD | 4.17 مليار USD | 1.4 مليار USD | 1.52 مليار USD | 1.5 مليار USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
State Street SPDR S&P 500 ETF1557.T94.47 مليار0.07%129.34 ترليون JPY0.09%122,850 JP¥+0.12%
Vanguard Morningstar Total Stock Market ETFVTI1.66 مليار0.07%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard S&P 500 ETFVOO1.39 مليار0.08%1.8 ترليون USD0.03%715.59 US$+0.61%
Vanguard Morningstar Mid-Cap ETFVO1.13 مليار0.50%226.4 مليار USD0.03%81.14 US$+0.92%
iShares Core S&P 500 ETFIVV645.72 مليون0.07%892.79 مليار USD0.03%781.97 US$+0.60%
State Street SPDR S&P 500 ETFSPY596.95 مليون0.07%817.2 مليار USD0.09%778.57 US$+0.60%
Vanguard Morningstar Value ETFVTV499.21 مليون0.19%262.4 مليار USD0.03%220.59 US$+0.44%
Vanguard Morningstar Mid-Cap Growth ETFVOT401.43 مليون1.17%34.1 مليار USD0.05%302.48 US$+1.55%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
Vanguard Morningstar Mid-Cap Growth ETFVOTالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.